Replies to post #139062 on Biotech Values

[DewDiligence]

Showing superiority to a good drug is always going to be very tough.

True; however, what’s even tougher these days is getting third-party payers to pay a high price for a branded drug that isn’t statsig superior to a drug that’s generic by the time the new branded drug hits the market.